Novo Nordisk: conclusive weight loss trial
(CercleFinance.com) - Novo Nordisk reports that a Phase III trial has demonstrated the efficacy and safety of CagriSema, a fixed combination of cagrilintide and semaglutide, for weight loss.
After 68 weeks, CagriSema achieved an average weight loss of 22.7%, outperforming cagrilintide (11.8%), semaglutide (16.1%) and placebo (2.3%).
In addition, 40.4% of patients achieved a weight loss of at least 25%.
Adverse events, mainly gastrointestinal, were generally mild to moderate.
According to Martin Holst Lange, Executive Vice President Development, these results pave the way for further research into the potential of CagriSema.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
After 68 weeks, CagriSema achieved an average weight loss of 22.7%, outperforming cagrilintide (11.8%), semaglutide (16.1%) and placebo (2.3%).
In addition, 40.4% of patients achieved a weight loss of at least 25%.
Adverse events, mainly gastrointestinal, were generally mild to moderate.
According to Martin Holst Lange, Executive Vice President Development, these results pave the way for further research into the potential of CagriSema.
Copyright (c) 2024 CercleFinance.com. All rights reserved.